Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms.

Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H.

Mod Pathol. 2016 Oct;29(10):1143-54. doi: 10.1038/modpathol.2016.112. Epub 2016 Jun 17.

2.

Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis.

Ellsworth RE, Toro AL, Blackburn HL, Decewicz A, Deyarmin B, Mamula KA, Costantino NS, Hooke JA, Shriver CD, Ellsworth DL.

Cancer Growth Metastasis. 2015 Jul 20;8:15-24. doi: 10.4137/CGM.S29490. eCollection 2015.

3.

Positive Association of Fibroadenomatoid Change with HER2-Negative Invasive Breast Cancer: A Co-Occurrence Study.

Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Liu J, Kvecher L, Fantacone-Campbell JL, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H.

PLoS One. 2015 Jun 22;10(6):e0129500. doi: 10.1371/journal.pone.0129500. eCollection 2015.

4.

Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.

Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H.

Oncogene. 2016 Mar 17;35(11):1373-85. doi: 10.1038/onc.2015.193. Epub 2015 Jun 22.

5.

Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.

Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H.

Breast Cancer Res. 2013;15(5):R73.

6.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.

Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H.

Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.

7.

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.

Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H.

Breast Cancer Res. 2012 Oct 4;14(5):R130. doi: 10.1186/bcr3328.

8.

Comprehensive molecular portraits of human breast tumours.

Cancer Genome Atlas Network.

Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.

9.

Differential gene expression in primary breast tumors associated with lymph node metastasis.

Ellsworth RE, Field LA, Love B, Kane JL, Hooke JA, Shriver CD.

Int J Breast Cancer. 2011;2011:142763. doi: 10.4061/2011/142763. Epub 2011 May 15.

10.

DW4TR: A Data Warehouse for Translational Research.

Hu H, Correll M, Kvecher L, Osmond M, Clark J, Bekhash A, Schwab G, Gao D, Gao J, Kubatin V, Shriver CD, Hooke JA, Maxwell LG, Kovatich AJ, Sheldon JG, Liebman MN, Mural RJ.

J Biomed Inform. 2011 Dec;44(6):1004-19. doi: 10.1016/j.jbi.2011.08.003. Epub 2011 Aug 22.

11.

Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women.

Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE.

Cancer. 2012 Mar 1;118(5):1334-44. doi: 10.1002/cncr.26405. Epub 2011 Jul 28.

12.

Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H.

J Clin Oncol. 2011 Jun 20;29(18):2448-58. doi: 10.1200/JCO.2010.30.3552. Epub 2011 May 16.

13.

Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues.

Bateman NW, Sun M, Bhargava R, Hood BL, Darfler MM, Kovatich AJ, Hooke JA, Krizman DB, Conrads TP.

J Proteome Res. 2011 Mar 4;10(3):1323-32. doi: 10.1021/pr101073s. Epub 2011 Jan 19.

PMID:
21155598
14.

Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression.

Ellsworth RE, Ellsworth DL, Weyandt JD, Fantacone-Campbell JL, Deyarmin B, Hooke JA, Shriver CD.

Ann Surg Oncol. 2010 Jun;17(6):1688-94. doi: 10.1245/s10434-010-0910-x. Epub 2010 Jan 27.

PMID:
20107913
15.

Genomic instability in the breast microenvironment? A critical evaluation of the evidence.

Holliday C, Rummel S, Hooke JA, Shriver CD, Ellsworth DL, Ellsworth RE.

Expert Rev Mol Diagn. 2009 Oct;9(7):667-78. doi: 10.1586/erm.09.55. Review.

PMID:
19817552
16.

Molecular changes in primary breast tumors and the Nottingham Histologic Score.

Ellsworth RE, Hooke JA, Love B, Ellsworth DL, Shriver CD.

Pathol Oncol Res. 2009 Dec;15(4):541-7. doi: 10.1007/s12253-009-9151-3. Epub 2009 Feb 5.

PMID:
19194786
17.

Genomic heterogeneity of breast tumor pathogenesis.

Ellsworth RE, Hooke JA, Shriver CD, Ellsworth DL.

Clin Med Oncol. 2009 Jul 29;3:77-85.

18.

A gene expression signature that defines breast cancer metastases.

Ellsworth RE, Seebach J, Field LA, Heckman C, Kane J, Hooke JA, Love B, Shriver CD.

Clin Exp Metastasis. 2009;26(3):205-13. doi: 10.1007/s10585-008-9232-9. Epub 2008 Dec 27.

PMID:
19112599
19.

Environmental chemicals and breast cancer risk--a structural chemistry perspective.

Weyandt J, Ellsworth RE, Hooke JA, Shriver CD, Ellsworth DL.

Curr Med Chem. 2008;15(26):2680-701. Review.

PMID:
18991630
20.

Amplification of HER2 is a marker for global genomic instability.

Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD.

BMC Cancer. 2008 Oct 14;8:297. doi: 10.1186/1471-2407-8-297.

Supplemental Content

Loading ...
Support Center